FIELD: medicine.
SUBSTANCE: invention concerns medicine area, namely, internal illnesses, and can be used for differential diagnostics of alcoholic and non-alcoholic steatohepatitis. Determine concentration of uroporphyrin (UP) and coproporphyrin (CP) in urine, and also content of CP and a protoporphyrin (PP) in feces at the patient with the established steatohepatitis diagnosis. Depending on set of their value, diagnose alcoholic steatohepatitis (ASH) or non-alcoholic steatohepatitis (NASH).
EFFECT: possibility to differentiate steatohepatitis of alcoholic and non-alcoholic etiology.
1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATING PORPHYRIA CUTANEA TARDA | 2003 |
|
RU2253454C1 |
| METHOD FOR PREDICTION OF PROGRESSIVE CLINICAL COURSE OF EARLY FORMS OF NON-ALCOHOLIC FATTY LIVER DISEASE | 2020 |
|
RU2768466C1 |
| STRUCTURALLY ENHANCED OXYGEN-CONTAINING FATTY ACIDS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | 2018 |
|
RU2820995C2 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF STEATOSIS AND NON-ALCOHOLIC STEATOHEPATITIS IN FEMALES | 2020 |
|
RU2744021C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF LIVER STEATOSIS AND NON-ALCOHOLIC STEATOHEPATITIS IN MEN | 2020 |
|
RU2753455C1 |
| NALMEFEN, NALTREXONE OR DERIVATIVES THEREOF FOR USE IN TREATING (NON)-ALCOHOLIC STEATOHEPATITIS OR NON-ALCOHOLIC FATTY LIVER DISEASE | 2017 |
|
RU2717677C1 |
| METHOD OF TREATING NON-ALCOHOLIC STEATOHEPATITIS WITH APPLICATION OF DALARGIN MAGNETOPHORESIS | 2011 |
|
RU2473325C1 |
| METHOD OF TREATING PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS ON BACKGROUND OF METABOLIC SYNDROME | 2015 |
|
RU2595815C1 |
| METHOD FOR TREATMENT OF PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE USING SPECIALIZED FOOD PRODUCT | 2021 |
|
RU2761164C1 |
| METHOD OF MODELING NON-ALCOHOLIC STEATOHEPATITIS IN RATS | 2009 |
|
RU2394281C1 |
